Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf 66

Rocha, Claudia; Murillo, Luis A.; Mora, Ana L.; Rojas, Mauricio; Franco, Leticia Sánchez; Côté, Johanne; Valero, M.V.; Moreno, Alberto; Amador, Roberto; Nuñez, F.; Coronell, Carlos; Patarroyo, Manuel E.

doi:10.1111/j.1365-3024.1992.tb00009.x

Cited by 23 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody levels fell rapidly after administration of the third dose of vaccine and showed little increase during the following rainy season, although 55% of children experienced an attack of malaria during this period. The higher immunogenicity of SPf66 produced in Colombia compared with that produced in the USA may reflect differences in the alum used in vaccine formulation but the significance of these differences is uncertain as no correlation has been found between antibody levels to SPf66 as measured by ELISA and biologically active antibodies (Rocha et a/. 1992).…”

Section: Study Of Spf66 In Gambian Infantsmentioning

confidence: 99%

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants

Leach

Drakeley²,

D’Alessandro

et al. 1995

Parasite Immunology

View full text Add to dashboard Cite

A pilot safety and immunogenicity trial of the malaria vaccine SPf66 has been undertaken in 150 Gambian infants. No significant systemic side effects were recorded but modest local reactions were seen after the administration of a third 1.0 mg dose. SPf66 produced in Colombia was more immunogenic than SPf66 produced in the USA and a 1.0 mg dose of each vaccine gave higher antibody levels than a 0.5 mg dose. However, antibody levels fell rapidly after administration of the third dose of vaccine and showed little change over the following malaria transmission season. The incidence of clinical malaria was higher among children who received SPf66 than among children who received inactivated polio vaccine, the effect being most marked among children who received 1.0 mg Colombian SPf66. As the trial was not designed to measure the effect of SPf66 on morbidity from malaria, the significance of this finding is uncertain.

show abstract

Section: Study Of Spf66 In Gambian Infantsmentioning

confidence: 99%

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants

Leach

Drakeley²,

D’Alessandro

et al. 1995

Parasite Immunology

View full text Add to dashboard Cite

show abstract

“…In in¯uenza virus antigen-primed mice, SPf66-IRIV elicited IgG against the SPf66 peptide vaccine more consistently than SPf(66) n adsorbed to alum, which has been used in clinical trials and, according to dose ®nding studies [29], requires relatively high doses to yield consistent humoral immune responses. For adults, the best immunization schedule has been found to consist of three doses, each containing 2 mg of synthetic peptide [29]. The generation of MoAb against SPf66 from a SPf66-IRIV-immunized mouse demonstrates that a portion of the anti-SPf66 antibodies elicited bind to P. falciparum blood stage parasites.…”

Section: Discussionmentioning

confidence: 99%

Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine

Pöltl-Frank

Zurbriggen

Helg

et al. 1999

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Immunopotentiating reconstituted influenza virosomes (IRIV) were used as a delivery system for the synthetic peptide-based malaria vaccine SPf66. The reduced SPf66 peptide molecules containing terminal cysteine residues were covalently attached to phosphatidylethanolamine with the heterobifunctional crosslinker gamma-maleimidobutyric acid N-hydroxysuccinimide ester. The SPf66-phosphatidylethanolamine was incorporated into IRIV and BALB/c mice were immunized twice by intramuscular injection with peptide-loaded virosomes. Titres of elicited anti-SPf66 IgG were determined by ELISA. These titres were significantly higher and the required doses of antigen were lower, when mice had been preimmunized with a commercial whole virus influenza vaccine. After preimmunization with the influenza vaccine, SPf66-IRIV elicited far more consistently anti-SPf66 antibody responses than SPf(66)n adsorbed to alum. MoAb produced by four B cell hybridoma clones derived from a SPf66-IRIV-immunized mouse cross-reacted with Plasmodium falciparum blood stage parasites in immunofluorescence assays. All four MoAbs were specific for the merozoite surface protein-1 (MSP-1)-derived 83.1 portion of SPf66. Sequencing of their functionally rearranged kappa light chain variable region genes demonstrated that the four hybridomas were generated from clonally related splenic B cells. Biomolecular interaction analyses (BIA) together with these sequencing data provided evidence for the selection of somatically mutated affinity-matured B cells upon repeated immunization with SPf66-IRIV. The results indicate that IRIV are a suitable delivery system for synthetic peptide vaccines and thus have a great potential for the design of molecularly defined combined vaccines targeted against multiple antigens and development stages of one parasite, as well as against multiple pathogens.

show abstract

“…The recommended dose of 0.5 ml was applied subcutaneously in the deltoid region. 22 A surveillance system for adverse reaction detection was set up during every planned vaccination. Frequency, intensity, and description of any adverse effect were systematically recorded.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of SPf66 malaria vaccine efficacy in Brazil.

Urdaneta¹,

Prata²,

Struchiner³

et al. 1998

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

This paper reports the efficacy results of the randomized, placebo-controlled, field trial of SPf66 malaria vaccine in Costa Marques, Rondonia, Brazil. This region is characterized by the seasonal distribution of Plasmodium falciparum and P. vivax infections, and the recent occupation by migrants from nonendemic areas. A total of 800 individuals of both sexes, ranging in age from seven to 60 years, were included in the study. Of the initial cohort, 572 participants completed the vaccination schedule. Clinical and parasitologic evaluations were obtained by active and passive searches on a periodic basis. The overall protective efficacy against P. falciparum infections was Ϫ1.6% (Ϫ32.9% to 22.4%), and 14.1% (Ϫ17.0% to 36.9%) for the first episode. The overall protective efficacy for P. vivax infections was Ϫ19.7% (Ϫ44.8% to 1.03%), and Ϫ10.8% (Ϫ41.1% to 12.8%) for the first episode. No statistical evidence of an overall significant protective effect of SPf66 malaria vaccine against P. falciparum and P. vivax malaria was obtained in this trial. * IDv and IDp ϭ incidence density rates in the vaccinated and placebo groups. † VE (%) ϭ vaccine efficacy estimates; CI ϭ confidence interval.

show abstract

Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf 66

Cited by 23 publications

References 15 publications

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants

Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine

Evaluation of SPf66 malaria vaccine efficacy in Brazil.

Contact Info

Product

Resources

About